Compare GameStop Corp. (GME) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Recursion Pharmaceuticals Inc — how do they compare? GameStop Corp. trades at $18.57 (market cap $8.44B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: GameStop Corp. is far larger — about 4.7× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| GME | RXRX | |
|---|---|---|
Market Cap | $8.44B | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $6.79 |
52-Week Low | $18.79 | $2.84 |
Enterprise Value | $4.42B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $18.57, down 1.2% with bearish technical signals from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant turnaround to profitability, achieving a 20.45% net income margin in 2025. Recent news highlights strategic shifts including potential partnership discussions with eBay instead of a full acquisition. Cash position strengthened to $4.77 billion following a $3.85 billion net cash inflow in 2025.
The outlook remains mixed with strong profitability improvements offset by bearish technical indicators and cautious analyst sentiment. Investment opportunity exists in the company's operational turnaround and cash-rich balance sheet, while risks include potential shareholder dilution from recent debt conversions and ongoing competitive pressures in the retail gaming sector.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
